Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2025 | Buy → Hold | Berenberg | |
| 4/15/2025 | $35.25 | Neutral | Exane BNP Paribas |
| 2/12/2025 | Equal-Weight | Morgan Stanley | |
| 11/15/2024 | Buy → Hold | Deutsche Bank | |
| 11/12/2024 | $53.00 → $39.50 | Buy → Hold | Jefferies |
| 10/31/2024 | Buy → Neutral | Guggenheim | |
| 7/8/2024 | Buy → Neutral | UBS | |
| 5/30/2024 | $47.00 | Neutral | Goldman |
Berenberg downgraded GlaxoSmithKline from Buy to Hold
Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25
Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight
New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action Originally launched in 2022, Vaccine Track remains the only publicly accessible source for month-by-month immunization trends across a variety of adult vaccines, enabling analyses that could uncover possible drivers Vaccine Track can help public health organizations and providers identify gaps and better target their efforts GSK plc (LSE/NYSE:GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immunization activity in the US. Users can now explore vaccination trends acros
NORWALK, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation® (MMRF®) today announced that a team of hikers, including multiple myeloma patients and advocates, will take on the rugged trails of New Hampshire's White Mountains as part of the Moving Mountains for Multiple Myeloma® (MM4MM) program. Sponsored by GSK plc (LSE/NYSE:GSK), the trek aims to raise awareness of multiple myeloma and generate critical funds to accelerate a cure for multiple myeloma. The hike will take place October 5 – 9, 2025. "Now in its ninth year, MM4MM has made tremendous progress and united hundreds of patients, caregivers, and supporters to raise funds that go directly to advancing
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPDAdditional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completionJIANGSU, China, July 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE:GSK) to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031. The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for the
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab
SC 13G/A - GSK plc (0001131399) (Subject)
SC 13G/A - GSK plc (0001131399) (Subject)
SC 13G/A - GSK PLC (0001131399) (Subject)
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U